Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation

Transplantation

Volumn 89, Issue 11, 2010, Pages 1354-1361

  Petropoulou, Anna D ^a   Porcher, Raphael ^a   Herr, Andrée Laure ^a   Devergie, Agnès ^a   Brentano, Thomas Funck ^a   Ribaud, Patricia ^a   Pinto, Fernando O ^a   Rocha, Vanderson ^a   Peffault De Latour, Régis ^a   Orcel, Philippe ^a   Socié, Gérard ^a   Robin, Marie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Allogeneic hematopoietic stem cell transplantation.; Avascular necrosis; Osteoporosis

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CORTICOSTEROID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AVASCULAR NECROSIS; BONE DISEASE; BONE TURNOVER; CHILD; CHILD HEALTH; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION;

ADOLESCENT; ADULT; BONE AND BONES; BONE DENSITY; BONE DISEASES; CHILD; COLLAGEN TYPE I; CYCLOSPORINE; FEMALE; FRACTURES, BONE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; NECROSIS; PEPTIDES; RISK FACTORS; SEX CHARACTERISTICS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 77953362782     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181d84c8e     Document Type: Article

References (39)

1. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: Clinical aspects. Biol Blood Marrow Transplant 2000; 6: 175.
2. Kelly PJ, Atkinson K, Ward RL, et al. Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation 1990; 50: 881.
3. Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: A long-term follow-up. Blood 2004; 103: 3635.
4. Carlo-Stella C, Tabilio A, Regazzi E, et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplant 1997; 20: 465.
5. Krolner B, Toft B. Vertebral bone loss: An unheeded side effect of therapeutic bed rest. Clin Sci (Lond) 1983; 64: 537.
6. Orcel P, Denne MA, de Vernejoul MC. Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology 1991; 128: 1638.
7. Andersson R, Rundgren A, Rosengren K, et al. Osteoporosis after long-term corticosteroid treatment of giant cell arteritis. J Intern Med 1990; 227: 391.
8. Stern JM, Chesnut CH III, Bruemmer B, et al. Bone density loss during treatment of chronic GVHD. Bone Marrow Transplant 1996; 17: 395.
9. Socie G, Selimi F, Sedel L, et al. Avascular necrosis of bone after alloge-neic bone marrow transplantation: Clinical findings, incidence and risk factors. Br J Hematol 1994; 86: 624.
10. Wiesmann A, Pereira P, Bohm P, et al. Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options. Bone Marrow Transplant 1998; 22: 565.
11. Schulte CM, Beelen DW. Avascular osteonecrosis after allogeneic he-matopoietic stem-cell transplantation: Diagnosis and gender matter. Transplantation 2004; 78: 1055.
12. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295.
13. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204.
14. Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update. J Intern Med 1998; 244: 271.
15. Bianchi ML, Baim S, Bishop NJ, et al. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol 2010; 25: 37.
16. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800.
17. Stern JM, Sullivan KM, Ott SM, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: A prospective study. Biol Blood Marrow Transplant 2001; 7: 257.
18. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: Analysis of risk factors for 4388 patientsby the Societe FrancaisedeGreffedeMoelle (SFGM).Br J Hematol 1997; 97: 865.
19. Socie G, Mary JY, Esperou H, et al. Health and functional status ofadult recipients 1 year after allogeneic hematopoietic stem cell transplantation. Br J Hematol 2001; 113: 194.
20. Valimaki MJ, Kinnunen K, Volin L, et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: Effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999; 23: 355.
21. Kananen K, Volin L, Tahtela R, et al. Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 29: 33.
22. Kauppila M, Irjala K, Koskinen P, et al. Bone mineral density after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 885.
23. Kashyap A, Kandeel F, Yamauchi D, et al. Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study. Biol Blood Marrow Transplant 2000; 6: 344.
24. Yao S, McCarthy PL, Dunford LM, et al. High prevalence ofearly-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008; 41: 393.
25. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648.
26. Garnero P, Ferreras M, Karsdal MA, et al. The typeIcollagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003; 18: 859.
27. Nishizawa Y, Nakamura T, Ohata H, et al. Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). J Bone Miner Metab 2001; 19: 338.
28. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189.
29. Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 337.
30. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018.
31. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653.
32. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382.
33. Fan SL, Almond MK, Ball E,et al. Pamidronate therapyasprevention of bone loss following renal transplantation. Kidney Int 2000; 57: 684.
34. Shane E, Rodino MA, McMahon DJ, et al. Prevention of bone loss after heart transplantation with antiresorptive therapy:Apilot study.J Heart Lung Transplant 1998; 17: 1089.
35. Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapyinyoung patients with multiple sclerosis. J Clin Endocrinol Metab 2004; 89: 4923.
36. Katz IA, Takizawa M, Jaffe II, et al. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. Transplantation 1991; 52: 571.
37. Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994; 57: 1231.
38. Durieux S, Mercadal L, Orcel P, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002; 74: 496.
39. Ebeling PR, Thomas DM, Erbas B, et al. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 1999; 14: 342.